Company Filing History:
Years Active: 2015-2016
Title: Geun-Bae Rha: Innovator in Monoclonal Antibody Research
Introduction
Geun-Bae Rha is a prominent inventor based in Cheongju-si, South Korea. He has made significant contributions to the field of biomedical research, particularly in the development of human monoclonal antibodies. With a total of 3 patents to his name, Rha's work focuses on innovative solutions for cancer treatment.
Latest Patents
One of Rha's latest patents is titled "Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof." This invention pertains to human monoclonal antibodies that neutralize vascular endothelial growth factor receptors. Specifically, it involves human ScFv molecules that inhibit angiogenesis and can be used in cancer treatment. The disclosed monoclonal antibody demonstrates excellent neutralizing ability in living cells, outperforming commercially available antibodies against vascular endothelial growth factor receptors. Furthermore, it shows the capability to neutralize these receptors in both humans and animal models, including mice and rats. This advancement holds promise for anticancer studies and effective cancer therapies.
Career Highlights
Geun-Bae Rha is associated with Pharmabcine Inc., where he continues to push the boundaries of medical research. His work has garnered attention for its potential impact on cancer treatment and therapeutic applications.
Collaborations
Rha collaborates with notable colleagues, including Jin-San Yoo and Weon-Sup Lee, who contribute to his research endeavors and innovations.
Conclusion
Geun-Bae Rha's contributions to monoclonal antibody research exemplify the importance of innovation in the fight against cancer. His patents and ongoing work at Pharmabcine Inc. highlight his commitment to advancing medical science and improving patient outcomes.